Literature DB >> 6165258

Factors influencing serum protein binding of lidocaine in humans.

P J McNamara, R L Slaughter, J A Pieper, M G Wyman, D Lalka.   

Abstract

Several factors that may affect protein binding of lidocaine in human serum were studied in normal volunteers. Evidence was obtained for the presence of two classes of lidocaine binding sites with strikingly different affinity constants (k) and capacities (nP); k1 equals 1.3 x 10(5)M(-1), n1P1 equals 1.7 x 10(-5)M, and k2 equals 6.4 x 10(1)M(-1), n2P2 equals 6.9 x 10(-3)M. The low affinity binding sites are probably on serum albumin, whereas the high affinity site may be located on alpha 1 acid glycoprotein. At a lidocaine serum concentration of approximately 1.4 microgram/ml, it was observed that acidosis (pH 7.4 leads to 7.2) caused lidocaine-free fraction to increase from 0.29 to 0.36 (p less than 0.01) and that the addition of the lidocaine metabolites 3-hydroxylidocaine, 4-hydroxylidocaine, monoethylglycinexylidide, and glycinexylidide had no effect on the binding of lidocaine. Bupivacaine, disopyramide, and quinidine (in concentrations that are observed clinically) caused a significant increase (p less than 0.01) in the free fraction of lidocaine in serum (23%, 21%, and 34%, respectively. Interestingly, N-depropyl disopyramide, dihydroquinidine, procainamide, N-acetyl procainamide, and propranolol had no effect on lidocaine binding.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165258

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  21 in total

Review 1.  [Complications of peripheral regional anesthesia].

Authors:  M Neuburger; J Büttner
Journal:  Anaesthesist       Date:  2011-11       Impact factor: 1.041

2.  Local anesthetics: a century of progress.

Authors:  J A Yagiela
Journal:  Anesth Prog       Date:  1985 Mar-Apr

3.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  Protein binding of cocaine in human serum.

Authors:  D J Edwards; S K Bowles
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

5.  Lidocaine protein binding in preeclampsia.

Authors:  M B Bottorff; J A Pieper; B A Boucher; T J Hoon; J Ramanathan; B M Sibai
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

7.  High-throughput analysis of drug dissociation from serum proteins using affinity silica monoliths.

Authors:  Michelle J Yoo; David S Hage
Journal:  J Sep Sci       Date:  2011-06-10       Impact factor: 3.645

8.  The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

Authors:  N D Bax; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of epidural and spinal anaesthesia.

Authors:  A G Burm
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.